In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sarepta Therapeutics, Inc.

https://www.sarepta.com/

Latest From Sarepta Therapeutics, Inc.

Coronavirus Update: Large Study Boosts Case For Vaccine Mixing

Results from a large Swedish study provide further evidence that mixing different COVID-19 vaccines boosts effectiveness. Meanwhile, Japan plans new funding to support the home-grown development of coronavirus and other vaccines. 

Coronavirus COVID-19 Vaccines

J&J Expects A Commercial COVID-19 Vaccine Market By Late 2022/2023

The company is currently providing its COVID-19 vaccine on a not-for-profit basis but expects that will change as the pandemic phase of the crisis abates.

Sales & Earnings Coronavirus COVID-19

Potential For Califf’s Second Term As US FDA Commissioner Surprises, Excites Stakeholders

Many supporters believe Robert Califf checks all the boxes, but if nominated he would also face many familiar confirmation challenges.

FDA Leadership

Oyster Point Prepares Major Push For New Dry Eye Drug

Execs told Scrip they hope to get Tyrvaya (varenicline) onto formularies and aim for pricing that would make its nasal spray competitive with Restasis and Xiidra.

Approvals Ophthalmic
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Other Names / Subsidiaries
    • AVI BioPharma, Inc.
    • Ercole Biotech, Inc.
    • Myonexus Therapeutics, Inc.
UsernamePublicRestriction

Register